BioCentury
ARTICLE | Company News

Mylan pays $465M in DOJ settlement

October 7, 2016 7:00 AM UTC

Mylan N.V. (NASDAQ:MYL) said it agreed to a $465 million settlement with the U.S. Department of Justice and other government entities that will "resolve questions that have been raised" about the classification of Mylan's EpiPen epinephrine auto-injector in the Medicaid Drug Rebate Program. The company said the settlement terms "do not provide for any finding of wrongdoing."

In a September memo, the National Association of Medicaid Directors suggested that Mylan was taking advantage of the program because classification of EpiPen as a generic allows the company to pay smaller rebates than those for branded drugs (see BioCentury Extra, Sept. 20). ...